(Q35015986)

5 August 2017

title

A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis (English)

1 reference

amyotrophic lateral sclerosis

5 August 2017

main subject

phase II clinical trial

0 references

0 references

author name string

Robert M Pascuzzi

1

1 reference

5 August 2017

Jeremy Shefner

2

1 reference

5 August 2017

Amy S Chappell

3

1 reference

5 August 2017

John S Bjerke

4

1 reference

5 August 2017

Roy Tamura

5

1 reference

5 August 2017

Vinay Chaudhry

6

1 reference

5 August 2017

Lora Clawson

7

1 reference

5 August 2017

Lisa Haas

8

1 reference

5 August 2017

Jeffrey D Rothstein

9

1 reference

5 August 2017

publication date

1 May 2010

1 reference

Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders

5 August 2017

published in

1 reference

5 August 2017

volume

11

1 reference

5 August 2017

issue

3

1 reference

5 August 2017

page(s)

266-271

1 reference

A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F17482960903307805

Mutations in the glutamate transporter EAAT2 gene do not cause abnormal EAAT2 transcripts in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F17482960903307805

AMPA receptor-mediated slow neuronal death in the rat spinal cord induced by long-term blockade of glutamate transporters with THA.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F17482960903307805

Impaired glutamate uptake and EAAT2 downregulation in an enterovirus chronically infected human glial cell line.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F17482960903307805

Current hypotheses for the underlying biology of amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F17482960903307805

Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F17482960903307805

Selective loss of glial glutamate transporter GLT‐1 in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F17482960903307805

Altered expression of the glutamate transporter EAAT2b in neurological disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F17482960903307805

Crosstalk between astrocytes and motor neurons: what is the message?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F17482960903307805

The AMPA receptor antagonist NBQX prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F17482960903307805

From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F17482960903307805

A crossover, add-on trial of talampanel in patients with refractory partial seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F17482960903307805

Ca(2+)-permeable AMPA receptors and selective vulnerability of motor neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F17482960903307805

Protection from fatal viral encephalomyelitis: AMPA receptor antagonists have a direct effect on the inflammatory response to infection

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F17482960903307805

Talampanel a non-competitive AMPA-antagonist attenuates caspase-3 dependent apoptosis in mouse brain after transient focal cerebral ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F17482960903307805

Riluzole. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F17482960903307805

Talampanel, a new antiepileptic drug: single- and multiple-dose pharmacokinetics and initial 1-week experience in patients with chronic intractable epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F17482960903307805

10.3109/17482960903307805

21 January 2018

Identifiers

DOI

1 reference

5 August 2017

1 reference